Kodiak Sciences Announces Proposed Offering of Common Stock

Rhea-AI Summary

Kodiak Sciences Inc. (Nasdaq: KOD) has announced a proposed underwritten public offering of $400 million of its common stock, with underwriters granted a 30-day option to purchase an additional $60 million. The offering is subject to market conditions and may not complete as planned. J.P. Morgan, Morgan Stanley, Jefferies, and Evercore ISI are the joint book-running managers. The shares are being offered under a previously filed shelf registration statement that became effective on November 16, 2020.

Positive

• The offering aims to raise $400 million, potentially providing significant capital for research and development.
• Additional $60 million could be raised if the underwriters exercise their option, enhancing financial flexibility.

Negative

• The public offering may result in shareholder dilution.
• Market conditions may affect the completion and size of the offering.

PALO ALTO, Calif., Nov. 16, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced that it has commenced an underwritten public offering of $400,000,000 of shares of its common stock. In connection with the proposed offering, Kodiak Sciences expects to grant the underwriters a 30-day option to purchase up to an additional $60,000,000 of shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares in the proposed offering will be sold by Kodiak Sciences. The proposed offering is subject to market and other conditions, and there can be no assurances as to whether or when the proposed offering may be completed, or as to the actual size or terms of the proposed offering.

J.P. Morgan, Morgan Stanley, Jefferies and Evercore ISI are acting as joint book-running managers for the proposed offering.  Truist Securities is acting as lead manager for the proposed offering.

The shares described above are being offered by Kodiak Sciences pursuant to a shelf registration statement on Form S-3, including a base prospectus, that was previously filed by Kodiak Sciences with the Securities and Exchange Commission (the "SEC") and that became automatically effective on November 16, 2020. A preliminary prospectus supplement and accompanying prospectus relating to the proposed offering will be filed with the SEC and will be available on the SEC's website located at http://www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the proposed offering, when available, may be obtained from: J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at 866-803-9204 or by email at prospectus-eq_fi@jpmchase.com; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014 or by email at prospectus@morganstanley.com; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; or Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 36th Floor, New York, NY 10055, by telephone at (888) 474-0200, or by email at ecm.prospectus@evercore.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Kodiak Sciences Inc.
Kodiak (Nasdaq: KOD) is a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases. Founded in 2009, we are focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally. Kodiak's lead product candidate, KSI-301, is a novel anti-VEGF antibody biopolymer conjugate being developed for the treatment of retinal vascular diseases including age-related macular degeneration, a leading cause of blindness in elderly patients, and diabetic eye diseases, a leading cause of blindness in working-age patients.

Forward-Looking Statements
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based on historical fact and include, but are not limited to, statements regarding the completion, timing and size of the proposed public offering. Any forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties related to market conditions and satisfaction of customary closing conditions related to the proposed public offering. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in Kodiak Sciences' most recent Form 10-Q, as well as in the preliminary prospectus supplement related to the proposed public offering to be filed with the SEC. These forward-looking statements speak only as of the date hereof and Kodiak Sciences undertakes no obligation to update forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements.

Kodiak®, Kodiak Sciences®, ABC™, ABC Platform™ and the Kodiak logo are registered trademarks or trademarks of Kodiak Sciences Inc. in various global jurisdictions.

View original content:http://www.prnewswire.com/news-releases/kodiak-sciences-announces-proposed-offering-of-common-stock-301173937.html

SOURCE Kodiak Sciences Inc.

FAQ

What is the size of the Kodiak Sciences underwritten public offering?

Kodiak Sciences is proposing an offering of $400 million of its common stock.

Who are the joint book-running managers for Kodiak Sciences' offering?

The joint book-running managers are J.P. Morgan, Morgan Stanley, Jefferies, and Evercore ISI.

What potential impact does the offering have on Kodiak Sciences shareholders?

The offering may lead to shareholder dilution and depends on market conditions for completion.

When was the shelf registration statement for Kodiak Sciences filed?

The shelf registration statement was filed and became effective on November 16, 2020.

Is Kodiak Sciences offering additional shares in its public offering?

Yes, Kodiak Sciences has granted a 30-day option for underwriters to purchase up to an additional $60 million of shares.